Brief: Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
06/01/2025 23:16
Jan 6 (Reuters) - Generation Bio Co GBIO.O :
* GENERATION BIO TO APPLY CTLNP DELIVERY TECHNOLOGY TO
DEVELOP
SIRNA THERAPEUTICS FOR T CELL-DRIVEN AUTOIMMUNE DISEASES
Source text: ID:nGNXbZYGJ
Further company coverage: GBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Generation Bio
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Nodthera Appoints Geoff Mcdonough, M.D., As Independent Board Member